The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study
- 511 Downloads
Hand–foot syndrome (HFS) is a common adverse event that can be induced by capecitabine. It is hypothesized that capecitabine (Hoffmann-La Roche Inc.) based chemotherapy can cause overexpression of COX-2 in tumor and healthy tissue, which finally induced HFS in hands and feet. Based on this, we believed that a selected COX-2 inhibitor (celecoxib, Pfizer Pharmaceuticals LLC) could ease HFS. We designed a prospective clinical study to test the hypothesis.
From August 2008 to January 2010, 110 patients with stage II/III colorectal cancer who were eligible for adjuvant chemotherapy were enrolled in the study and divided into 4 groups by random, but 9 patients did not finish at least 4 cycles of chemotherapy. There were sixteen patients in capecitabine group, and fifteen patients in capecitabine and celecoxib group. Thirty-four patients were in XELOX (capecitabine plus oxaliplatine) group, and thirty-six patients in XELOX+ celecoxib group. All 101 patients finished chemotherapy and follow-up interviews.
The group that had received capecitabine and celecoxib had a significantly reduced frequency of >grade 1 hand–foot syndrome (29 vs. 72% P < 0.001), and >grade 2 (11.76% vs. 30% P = 0.024). Five patients experienced grade 3 HFS in capecitabine group and only 1 patient had grade 3 HFS in capecitabine and celecoxib group. There were 5 patients in capecitabine group who refused to go on chemotherapy because of HFS, but there was none in capecitabine and celecoxib group.
From the result of this study, we could learn that celecoxib could reduce HFS that was induced by capecitabine. So we recommend that celecoxib can be used in capecitabine-based chemotherapy.
KeywordsHand–foot syndrome Capecitabine Celecoxib Colorectal cancer Adjuvant chemotherapy Adverse event
We are very thankful to Zhi-heng Peng and Zi-yi Huang for the acquisition of data.
Conflict of interest
We declare that there is no conflict of interest in this study.
- Dong ZW, Qiao YL, Li LD, Chen YD, Wang RT, Lei TH et al (2002) Report of Chinese cancer control strategy. Chin Cancer 11:250–260Google Scholar
- Edward LIN, Jeffrey S, Morris et al (2002) Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 16:31–37Google Scholar
- Yong J, Wei W, Ping L et al (2007) Controlled clinical research of Celecoxib In prophylaxising side effects caused by Capecitabine. Chinese J Composite Clinical Hygiene 9:6–8Google Scholar